Literature DB >> 24982335

Validation of 2-mm tissue microarray technology in gastric cancer. Agreement of 2-mm TMAs and full sections for Glut-1 and Hif-1 alpha.

Felix Berlth1, Stefan P Mönig2, Hans A Schlösser2, Martin Maus2, Christoph T H Baltin2, Alexander Urbanski2, Uta Drebber3, Elfriede Bollschweiler2, Arnulf H Hölscher2, Hakan Alakus4.   

Abstract

BACKGROUND/AIM: Tissue Microarray (TMA) is a widely used method to perform high-throughput immunohistochemical analyses on different tissues by arraying small sample cores from paraffin-fixed tissues into a single paraffin block. TMA-technology has been validated on numerous cancer tissues and also for gastric cancer studies, although it has not been validated for this tumor tissue so far. The objective of this study was to assess, whether the 2-mm TMA-technology is able to provide representative samples of gastric cancer tissue.
MATERIALS AND METHODS: TMA paraffin blocks were constructed by means of 220 formalin-fixed and paraffin-embedded gastric cancer samples with a sample diameter of 2 mm. The agreement of immunohistochemical stainings of Glut-1 and Hif-1 alpha in TMA sections and the original full sections was calculated using kappa statistics and direct adjustment.
RESULTS: The congruence was substantial for Glut-1 (kappa 0.64) and Hif-1 alpha (kappa 0.70), but with an agreement of only 71% and 52% within the marker-positive cases of the full-section slides.
CONCLUSION: Due to tumor heterogeneity primarily, the TMA technology with a 2-mm sample core shows relevant limitations in gastric cancer tissue. Although being helpful for tissue screening purposes, the 2-mm TMA technology cannot be recommended as a method equal to full-section investigations in gastric cancer. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Glut-1; Hif-1 alpha; Tissue microarray; gastric cancer

Mesh:

Substances:

Year:  2014        PMID: 24982335

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

Review 1.  Preoperative staging of nodal status in gastric cancer.

Authors:  Felix Berlth; Seung-Hun Chon; Mickael Chevallay; Minoa Karin Jung; Stefan Paul Mönig
Journal:  Transl Gastroenterol Hepatol       Date:  2017-02-07

2.  A comparative study of RTK gene status between primary tumors, lymph-node metastases, and Krukenberg tumors.

Authors:  Guoping Ren; Xiaoling Wang; Bo Wang; Qiusu Tang; Liming Xu; Xiaodong Teng; Wei Ding
Journal:  Mod Pathol       Date:  2020-07-30       Impact factor: 7.842

3.  Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer.

Authors:  Floor J Backes; Christopher J Walker; Paul J Goodfellow; Erinn M Hade; Garima Agarwal; David Mutch; David E Cohn; Adrian A Suarez
Journal:  Gynecol Oncol       Date:  2016-03-10       Impact factor: 5.482

4.  ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer.

Authors:  K Trumpi; B L Emmink; A M Prins; M G H van Oijen; P J van Diest; C J A Punt; M Koopman; O Kranenburg; I H M Borel Rinkes
Journal:  J Cancer       Date:  2015-09-03       Impact factor: 4.207

5.  Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis.

Authors:  Zheng-Xiao Zhao; Lin-Wei Lu; Jian Qiu; Qiu-Ping Li; Fei Xu; Bao-Jun Liu; Jing-Cheng Dong; Wei-Yi Gong
Journal:  Oncotarget       Date:  2017-07-04

6.  Establishment of a [18F]-FDG-PET/MRI Imaging Protocol for Gastric Cancer PDX as a Preclinical Research Tool.

Authors:  Seong-Woo Bae; Felix Berlth; Kyoung-Yun Jeong; Yun-Suhk Suh; Seong-Ho Kong; Hyuk-Joon Lee; Woo Ho Kim; June-Key Chung; Han-Kwang Yang
Journal:  J Gastric Cancer       Date:  2020-02-21       Impact factor: 3.720

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.